- Conditions
- AML (Acute Myelogenous Leukemia), Acute Leukemia (Category), Acute Lymphoid Leukemia (ALL), CLL (Chronic Lymphocytic Leukemia), CML (Chronic Myelogenous Leukemia), Chronic Myelomonocytic Leukemia (CMML), Lymphoma, MDS (Myelodysplastic Syndrome), Myelofibrosis, Myeloproliferative Neoplasm (MPN), Prolymphocyctic Leukemia
- Interventions
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (25 mg/kg D3, D4), PTCy (50 mg/kg D3, D4), Permitted Concomitant Therapy, Post-transplant Abatacept, Post-transplant Mycophenolate mofetil, Post-transplant Ruxolitinib, Post-transplant Tacrolimus, Prohibited Concomitant Therapy, Study treatment compliance, Supportive Care: Blood Products, Supportive Care: Growth Factors, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Lipid elevations, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Seizure prophylaxis
- Drug · Procedure · Other
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the local directory fallback.
Local D1 index available.
- Conditions
- ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myelogenous Leukemia, Lymphoma, Non-Hodgkin, MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder
- Interventions
- Graft Manipulation (CD34+ Selection)
- Device
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoblastic Leukemia, CML (Chronic Myelogenous Leukemia), Chronic Lymphocytic Leukemia, MDS (Myelodysplastic Syndrome)
- Interventions
- MVST, MVSTr
- Biological
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphocytic Leukemia, CLL (Chronic Lymphocytic Leukemia), CML (Chronic Myelogenous Leukemia), MDS (Myelodysplastic Syndrome)
- Interventions
- Miltenyi system
- Combination Product
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland